DE:6DW Stock Latest News
Company AnnouncementsD.Western Therapeutics Applies to Move to TSE Standard Market22h ago
Company AnnouncementsD.Western Posts ¥51 Million Sales and ¥502 Million Parent-Attributable Loss22h ago
Company AnnouncementsD. Western Therapeutics Outlines Q2 FY12/26 Results and Outlook3M ago
Company AnnouncementsD.Western Therapeutics Posts Deeper Losses, Keeps 2026 Outlook Unchanged3M ago- Company AnnouncementsDWTI’s Bondlido Gains U.S. Sales Partner as Launch Plans Advance6M ago
Company AnnouncementsD.Western Therapeutics Posts Deeper Quarterly Loss and Cuts 2026 Sales Outlook6M agoCompany AnnouncementsD. Western Therapeutics Completes Global Phase III Follow-Up for Fuchs Drug K-3217M ago
Company AnnouncementsD. Western Therapeutics Outlines FY12/25 Results and FY12/26 Outlook9M ago- Company AnnouncementsD.Western Therapeutics Narrows Losses but Forecasts Deeper Red Ink in 20269M ago
- Company AnnouncementsD. Western Therapeutics Institute Outlines FY2025 Results and FY2026 Outlook9M ago
Company AnnouncementsDWTI’s Glaucoma Combination Eye Drop GLA-ALPHA Debuts in Singapore Through Kowa10M ago
Company AnnouncementsD. Western Therapeutics Expands Global Reach with New Ophthalmic Solution in Malaysia11M ago
Company AnnouncementsD.Western Therapeutics Advances to Phase III Trial for Regenerative Eye Treatment11M ago
- Company AnnouncementsD.Western Therapeutics Reports Financial Decline but Improved Equity12M ago
Company AnnouncementsD. Western Therapeutics Institute Reports Breakthrough in Dry Eye Treatment Research1y ago
Company AnnouncementsD. Western Therapeutics Gains FDA Approval for Bondlido Patch1y ago
Company AnnouncementsFDA Conditionally Approves New Name for D.Western’s Lidocaine Patch1y ago
Company AnnouncementsD.Western Therapeutics Institute Reports Decline in H1 2025 Financials1y agoCompany AnnouncementsD. Western Therapeutics Institute Unveils New Pipeline for Ocular Diseases1y ago
